Cullen/Frost Bankers’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.48M Sell
9,463
-4
-0% -$600 0.01% 307
2026
Q1
$1.45M Sell
9,467
-55
-0.6% -$8.43K 0.02% 300
2025
Q4
$1.31M Sell
9,522
-96
-1% -$12.6K 0.01% 315
2025
Q3
$1.23M Sell
9,618
-876
-8% -$107K 0.01% 310
2025
Q2
$1.27M Buy
10,494
+827
+9% +$93.2K 0.02% 295
2025
Q1
$1.08M Buy
9,667
+63
+0.7% +$6.71K 0.02% 305
2024
Q4
$935K Sell
9,604
-770
-7% -$82.1K 0.01% 318
2024
Q3
$1.19M Sell
10,374
-347
-3% -$39.4K 0.02% 285
2024
Q2
$1.14M Sell
10,721
-1,474
-12% -$148K 0.02% 283
2024
Q1
$1.18M Buy
12,195
+107
+0.9% +$11K 0.02% 282
2023
Q4
$1.22M Sell
12,088
-10,769
-47% -$1.04M 0.02% 278
2023
Q3
$2.33M Buy
22,857
+386
+2% +$39.2K 0.04% 230
2023
Q2
$2.27M Sell
22,471
-793
-3% -$79.3K 0.04% 237
2023
Q1
$2.14M Sell
23,264
-2,362
-9% -$206K 0.04% 238
2022
Q4
$2.32M Sell
25,626
-4,285
-14% -$361K 0.04% 231
2022
Q3
$2.27M Buy
29,911
+220
+0.7% +$18.2K 0.05% 218
2022
Q2
$2.51M Sell
29,691
-324
-1% -$28.4K 0.06% 217
2022
Q1
$2.63M Sell
30,015
-1,355
-4% -$117K 0.05% 224
2021
Q4
$2.74M Sell
31,370
-859
-3% -$71.3K 0.05% 222
2021
Q3
$2.64M Sell
32,229
-1,619
-5% -$146K 0.05% 224
2021
Q2
$3.09M Sell
33,848
-5
-0% -$445 0.06% 219
2021
Q1
$2.89M Sell
33,853
-5,671
-14% -$509K 0.06% 218
2020
Q4
$3.73M Sell
39,524
-1,233
-3% -$108K 0.09% 183
2020
Q3
$3.54M Buy
40,757
+3,277
+9% +$284K 0.09% 184
2020
Q2
$3.27M Buy
37,480
+976
+3% +$84.2K 0.09% 185
2020
Q1
$3.01M Sell
36,504
-1,450
-4% -$129K 0.1% 168
2019
Q4
$3.59M Sell
37,954
-17,685
-32% -$1.59M 0.1% 176
2019
Q3
$4.83M Sell
55,639
-6,133
-10% -$551K 0.14% 146
2019
Q2
$5.64M Sell
61,772
-161,980
-72% -$13.7M 0.17% 133
2019
Q1
$19.2M Buy
223,752
+29,472
+15% +$2.37M 0.59% 52
2018
Q4
$14.9M Sell
194,280
-72,987
-27% -$5.68M 0.56% 56
2018
Q3
$20.6M Sell
267,267
-19,525
-7% -$1.44M 0.65% 51
2018
Q2
$19.4M Sell
286,792
-17,308
-6% -$1.19M 0.6% 58
2018
Q1
$22M Buy
304,100
+16,411
+6% +$1.25M 0.65% 51
2017
Q4
$21.6M Buy
287,689
+5,068
+2% +$382K 0.69% 53
2017
Q3
$21.7M Sell
282,621
-3,608
-1% -$272K 0.71% 48
2017
Q2
$21.4M Sell
286,229
-7,059
-2% -$500K 0.72% 46
2017
Q1
$19.5M Sell
293,288
-14,949
-5% -$996K 0.67% 55
2016
Q4
$20.1M Buy
308,237
+77
+0% +$5K 0.69% 53
2016
Q3
$21.8M Sell
308,160
-3,410
-1% -$248K 0.78% 38
2016
Q2
$23M Sell
311,570
-26,793
-8% -$1.85M 0.85% 28
2016
Q1
$22M Sell
338,363
-1,317
-0.4% -$89.6K 0.82% 37
2015
Q4
$26.2M Buy
339,680
+2,372
+0.7% +$188K 0.99% 24
2015
Q3
$27.8M Buy
337,308
+1,249
+0.4% +$111K 1.1% 15
2015
Q2
$29.6M Buy
336,059
+1,336
+0.4% +$123K 1.1% 13
2015
Q1
$29.6M Sell
334,723
-1,512
-0.4% -$134K 1.11% 10
2014
Q4
$27.9M Buy
336,235
+8,711
+3% +$722K 1.07% 11
2014
Q3
$27.6M Buy
327,524
+232
+0.1% +$18.8K 1.12% 11
2014
Q2
$26.6M Buy
327,292
+8,971
+3% +$706K 1.07% 13
2014
Q1
$24.3M Buy
318,321
+13,150
+4% +$958K 1.04% 13
2013
Q4
$22M Buy
305,171
+33,176
+12% +$2.31M 0.97% 17
2013
Q3
$18.7M Buy
271,995
+2,059
+0.8% +$136K 0.92% 18
2013
Q2
$17.1M Buy
+269,936
New +$17.6M 0.9% 23

Other funds holding NVS

Cullen/Frost Bankers's NVS Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Novartis (NVS) stake by 0.04% in Q2 2026, selling an estimated $600 and leaving 9,463 shares worth $1.48M. The position accounts for 0.01% of the portfolio, ranked #307.

Cullen/Frost Bankers first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $29.6M in Q2 2015. 1,027 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Cullen/Frost Bankers held 9,463 shares of Novartis worth $1.48M as of Q2 2026.
  • Cullen/Frost Bankers sold 4 Novartis shares in Q2 2026, an estimated $600.
  • Novartis made up 0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #307 holding.
  • Cullen/Frost Bankers first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Cullen/Frost Bankers's Novartis position peaked at $29.6M in Q2 2015.
  • 1,027 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.